Critical Care

official impact factor 4.60

This article is part of the supplement: 24th International Symposium on Intensive Care and Emergency Medicine

Effect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I study

S Johansson, M Apajasalo, T Sarapohja and C Garratt

Critical Care 2004, 8(Suppl 1):P88 doi:10.1186/cc2555

Accesses  

  • Last 30 days: 20 accesses
  • Last 365 days: 178 accesses
  • All time: 2022 accesses